SUNNYVALE, Calif., June 6, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCBB: AMBS), a biotechnology company developing drug and diagnostic products for the treatment of Parkinson's disease and other nervous system disorders including Traumatic Brain Injury, today announced that it has been selected to participate in the National Investment Banking Association's 122nd Conference in New York City at Le Park Meridien Hotel June 7-8, 2012. Mr. Gerald Commissiong, Amarantus' President & CEO, will be a featured presenter.
"We are excited to present Amarantus to the investment community in New York City over the next few days at the NIBA event," said Gerald E. Commissiong, President & CEO of Amarantus. "This conference will allow Amarantus to engage with small-cap and micro-cap investors who can understand the tremendous value proposition that our Company represents. Amarantus is striving to become the leader in the development of new drug and diagnostic products for the brain. Our flagship MANF Program is a potential blockbuster opportunity."
NIBA is a national not-for-profit trade association of regional and independent brokerages, investment banking firms, institutional investors and related capital market service providers. Since its inception, NIBA member firms have successfully completed over 1000 equity offerings totaling approximately $10 billion in new capital for America's finest emerging growth companies. The member firms of NIBA represent over 8000 registered representatives with an estimated $78 billion in assets under management, and are responsible for 90% of all Initial Public Offerings under $20 million.
PRESENTATION INFORMATION AT A GLANCE:
Gerald Commissiong, President and Chief Executive Officer
June 7th, 2012 at 3pm ET in the Azekka Banquet Room
Le Parker Meridien, 119 West 56th Street, New York NY
About MANF (Mesencephalic-Astrocyte-derived Neurotrophic Factor)
MANF (Mesencephalic-Astrocyte-derived Neurotrophic Factor) is a protein that corrects protein misfolding, one of the major causes of apoptosis (cell death). This property provides a compelling rationale for the research and development of MANF-based products as therapeutics for human disease. The lead MANF product development effort is centered on a therapy for Parkinson's disease, currently funded by a research grant from the Michael J. Fox Foundation for Parkinson's Research and a secondary program funded by the Brewer Sports International developing new treatments for Traumatic Brain Injury. The Company also owns an inventory of 88 cell lines referred to as "PhenoGuard Cell Lines." MANF was the first therapeutic protein discovered from a PhenoGuard Cell Line. It is anticipated that additional therapeutic proteins useful for various therapeutic approaches to the Central Nervous System (CNS) will be identified from the Company's inventory of PhenoGuard Cell Lines.
About Amarantus BioSciences, Inc.
Amarantus BioSciences, Inc. is a development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat Parkinson's disease, Traumatic Brain Injury and other human diseases. The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for human disorders. For further information please visit http://www.Amarantus.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the possible benefits of MANF therapeutic applications and/or advantages presented by Amarantus' PhenoGuard technology, as well as statements about expectations, plans and prospects of the development of Amarantus' new product candidates. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including the risks that the anticipated benefits of the therapeutic drug candidates or discovery platforms, as well as the risks, uncertainties and assumptions relating to the development of Amarantus' new product candidates, including those identified under "Risk Factors" in Amarantus' most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and in other filings Amarantus periodically makes with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements Amarantus does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this presentation.
Amarantus Biosciences, Inc.
408.737.2734 x 102
|SOURCE Amarantus BioSciences, Inc.|
Copyright©2012 PR Newswire.
All rights reserved